Aflatoxin B₁ exposure and liver cirrhosis in Guatemala: a case–control study


ABSTRACT

Objective In Guatemala, cirrhosis is among the 10 leading causes of death, and mortality rates have increased lately. The reasons for this heavy burden of disease are not clear as the prevalence of prominent risk factors, such as hepatitis B virus, hepatitis C virus, and heavy alcohol consumption, appears to be low. Aflatoxin B₁ (AFB₁) exposure, however, appears to be high, and thus could be associated with the high burden of cirrhosis. Whether AFB₁ increases the risk of cirrhosis in the absence of viral infection, however, is not clear.

Design Cirrhosis cases (n=100) from two major referral hospitals in Guatemala City were compared with controls (n=200) from a cross-sectional study. Logistic regression was used to estimate the ORs and 95% CIs of cirrhosis and quintiles of AFB₁ in crude and adjusted models. A sex-stratified analysis was also conducted.

Results The median AFB₁ level was significantly higher among the cases (11.4 pg/mg) than controls (5.1 pg/mg). In logistic regression analyses, higher levels of AFB₁ were associated with cirrhosis (quintile 5 vs quintile 1, OR: 11.55; 95% CI 4.05 to 32.89). No attenuation was observed with adjustment by sex, ethnicity, hepatitis B virus status, and heavy alcohol consumption. A significantly increasing trend in association was observed in both models (p trend <0.01). Additionally, the cirrhosis–AFB₁ association was more prominent among men.

Conclusions The current study found a significant positive association between AFB₁ exposure and cirrhosis. Mitigation of AFB₁ exposure and a better understanding of additional risk factors may be important to reduce the burden of cirrhosis in Guatemala.

INTRODUCTION

Aflatoxin B₁ (AFB₁) is a known risk factor for hepatocellular carcinoma (HCC), the dominant type of liver cancer. In Guatemala, the estimated incidence of HCC is the highest in the Western hemisphere. The major risk factors for HCC in Guatemala are not well characterised, but the prevalence of AFB₁ exposure appears to be high. The great majority of HCCs (≥80%) develop in persons with pre-existing cirrhosis. Therefore, insights into the relationship between AFB₁ and cirrhosis could be informative.

With over one million deaths per year, cirrhosis is the 11th most common cause of death worldwide. In combination with HCC, cirrhosis accounts for 3.5% of all deaths globally. In Guatemala, cirrhosis is among the 10 leading causes of death and accounts for an estimated 3.4% of all premature deaths. In addition, mortality rates of cirrhosis have...
increased with an average annual per cent change of 14.4% over the past two decades, thus representing an important public health issue in Guatemala.

Cirrhosis is a severe chronic liver disease which occurs in response to liver injury, featuring encapsulation or replacement of the damaged liver tissue by scar tissue with distortion of the hepatic vasculature and architecture. The disease is often asymptomatic until complications such as variceal bleeding, ascites and jaundice occur. In the USA, Europe and some countries in Latin America, cirrhosis is a leading indication for liver transplantation. HCC and cirrhosis are known to share common risk factors, including heavy alcohol consumption, hepatitis B virus (HBV), hepatitis C virus (HCV), and the related metabolic abnormalities of obesity and non-alcoholic fatty liver disease (NAFLD). It has also been reported that AFB1 is associated with cirrhosis among persons infected with HBV or HCV. Whether AFB1 increases the risk of cirrhosis in the absence of viral infection, however, remains unclear.

In 2017, our group reported high levels of serum AFB1-albumin adducts and low prevalences of HBV (0.9%) and HCV (0.5%) infections in a cross-sectional study of Guatemalan adults. In addition, our group has found that the most important source of AFB1 exposure in the population was consumption of tortillas, a primary staple in the Guatemalan diet. This finding was consistent with prior evidence of high AFB1 levels in maize samples across the country. The current study was designed to assess the association between AFB1 and cirrhosis in Guatemala.

METHODS

Study population

One hundred cirrhosis cases were ascertained between February and November 2015 at two large public hospitals in Guatemala City (Hospital General San Juan de Dios and Hospital Roosevelt). The cases were outpatients recruited at the hospitals’ outpatient clinics and emergency rooms. Cirrhosis was diagnosed by abdominal ultrasonography using a quantitative scoring system, including morphological appearance of the liver surface, liver parenchymal texture, intrahepatic vascular structure and spleen size.

Controls were selected from a cross-sectional study of Guatemalan adults, aged 40 years and older, that was conducted in 2016. The cross-sectional study enrolled 461 individuals from five departments of Guatemala in order to determine the prevalence of risk factors for liver cancer. The study recruitment was based on a non-random household visit using maps of the community when available. Details of the study have been previously described. The selection of 200 controls for the current study was based on the residence of the cirrhosis cases, 83% of whom resided in the department of Guatemala or vicinity. Hence, 85% of the controls were chosen from the departments of Guatemala and Escuintla (approximately 64 kilometers from the capital city). Individuals in the cross-sectional study who reported a history of cirrhosis were not eligible to be controls in the current analysis (n=7).

Data collection

Study participants were interviewed by trained staff using a structured questionnaire that included information on sociodemographic characteristics (eg, age, sex, residence, ethnicity and occupation), alcohol and maize consumption, as well as use of medications. Study participants also donated blood samples which were used to determine hepatitis B surface antigen (HBsAg), antibody to hepatitis C virus (anti-HCV) and AFB1-lysine (AFB1-lys) adducts.

AFB1-lysine adduct assessments

The determination of AFB1-lys adduct levels was performed by isotope-dilution mass spectrometry at Dr. John D Groopman’s laboratory at the Johns Hopkins University Bloomberg School of Public Health. Adduct concentrations (pg/AFB1-lys/mL serum) were normalised to total serum albumin and expressed as pg AFB1-lys adduct/mg albumin. Details of the laboratory methods have been previously described.

Study covariates

The covariates used in the analysis included age, sex, ethnicity (indigenous vs not indigenous), residence (department of Guatemala and vicinity vs other departments), occupation (farmer vs other), heavy alcohol consumption (alcohol consumption ≥2 drinks for men or ≥1 drink for women per day in the last year, or report of a period in life where five or more drinks every day were consumed), HBsAg and anti-HCV.

Statistical analysis

Medians and IQRs were calculated for continuous variables, and percentages were used for categorical variables. To examine differences in the characteristics between cases and controls, t-tests or Wilcoxon rank-sum tests were used for continuous variables, and χ² or exact tests were used for categorical variables. Additionally, median and IQR of AFB1 for each covariate were computed among the controls, and the differences in the median were assessed by the Wilcoxon rank-sum test. Unconditional logistic regression was used to calculate the ORs and 95% CIs for the association between cirrhosis and the serum AFB1-albumin adduct levels by quintiles. A dose–response relationship between cirrhosis and AFB1 was examined, and p trends were calculated by scoring (1–5) the quintiles and including the score as a continuous variable in unadjusted and adjusted models. The logistic model selection was based on two different approaches: a stepwise variable selection procedure and examining the change in the estimated ORs by adding
Table 1  Sociodemographic, clinical and other characteristics of individuals by cirrhosis status

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total (N=300)</th>
<th>Cases (n=100)</th>
<th>Controls (n=200)</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (IQR)</td>
<td>55 (48–63)</td>
<td>54 (47–64)</td>
<td>56 (48–62)</td>
<td>0.07</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.22</td>
</tr>
<tr>
<td>Male</td>
<td>129 (43.0)</td>
<td>48 (48.0)</td>
<td>81 (40.5)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>171 (57.0)</td>
<td>52 (52.0)</td>
<td>119 (59.5)</td>
<td></td>
</tr>
<tr>
<td>Indigenous ethnicity, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.84</td>
</tr>
<tr>
<td>Yes</td>
<td>64 (21.3)</td>
<td>22 (22.0)</td>
<td>42 (21.0)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>236 (78.7)</td>
<td>78 (78.0)</td>
<td>158 (79.0)</td>
<td></td>
</tr>
<tr>
<td>Department of residence, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.57</td>
</tr>
<tr>
<td>Guatemala and vicinity</td>
<td>254 (84.7)</td>
<td>83 (83.0)</td>
<td>171 (85.5)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>46 (15.3)</td>
<td>17 (17.0)</td>
<td>29 (14.5)</td>
<td></td>
</tr>
<tr>
<td>Occupation, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.06</td>
</tr>
<tr>
<td>Farmer</td>
<td>9 (3.0)</td>
<td>6 (6.0)</td>
<td>3 (1.5)</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>291 (97.0)</td>
<td>94 (94.0)</td>
<td>197 (98.5)</td>
<td></td>
</tr>
<tr>
<td>Heavy alcohol consumption, n (%)†</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Yes</td>
<td>59 (19.8)</td>
<td>51 (52.0)</td>
<td>8 (4.0)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>239 (80.2)</td>
<td>47 (48.0)</td>
<td>192 (96.0)</td>
<td></td>
</tr>
<tr>
<td>HBsAg (seropositivity), n (%)†</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Yes</td>
<td>8 (2.7)</td>
<td>7 (7.0)</td>
<td>1 (0.5)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>290 (97.3)</td>
<td>93 (93.0)</td>
<td>197 (99.5)</td>
<td></td>
</tr>
<tr>
<td>Anti-HCV (seropositivity), n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.11</td>
</tr>
<tr>
<td>Yes</td>
<td>4 (1.3)</td>
<td>3 (3.0)</td>
<td>1 (0.5)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>296 (98.7)</td>
<td>97 (97.0)</td>
<td>199 (99.5)</td>
<td></td>
</tr>
<tr>
<td>AFB1-albumin adduct levels, median (IQR)</td>
<td>7.3 (3.5–14.6)</td>
<td>11.4 (5.7–25.7)</td>
<td>5.11 (2.4–12.0)</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

*P values for categorical variables were obtained from χ² test (sex, indigenous ethnicity, residence and heavy alcohol consumption) or exact test (occupation, HBsAg and HCV status), and for the continuous variables Wilcoxon test (AFB1-lysine) or t-test (age).
†Categories do not sum to the total due to missing data.

AFB1, aflatoxin B1; anti-HCV, antibody to hepatitis C virus; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus.

RESULTS

Table 1 shows the characteristics of the study participants. The median age of the participants was 55 years (IQR: 48–63). Of the participants, 57% were women. The majority (85%) of individuals resided in the departments of Guatemala and vicinity. Cirrhosis cases were more likely to report heavy alcohol consumption (52%) than were the controls (4%) (p<0.01). The prevalence of HBsAg was low (2.7%) but was statistically higher in cases (7%) than controls (0.5%) (p<0.01). The prevalence of anti-HCV was low (1.3%), and there was no significant difference in prevalence between the cases (3%) and controls (0.5%) (p=0.11). The median AFB1 level was significantly higher among the cases (11.4 pg/mg) than among the controls (5.11 pg/mg) (p<0.01).

Table 2 depicts the median values of AFB1-lys adducts by sociodemographic and other characteristics among the controls. Indigenous persons had a significantly higher median AFB1-lys adduct level than did non-indigenous persons (15.2 pg/mg vs 4.8 pg/mg, p<0.01). Similarly, individuals who resided outside the department of Guatemala and vicinity had a significantly higher median AFB1-lys adduct level than did the individuals who lived in the department of Guatemala and vicinity (17.8 pg/mg vs 4.9 pg/mg, p<0.01). No differences in median AFB1-lys adduct levels were observed by age, sex, occupation, excessive alcohol consumption, body mass index or HBsAg and anti-HCV status.

Table 3 shows the results of the logistic regression analysis for the association between cirrhosis and AFB1-lys adduct levels estimated as ORs. Higher levels of AFB1-lys covariates, yielding the following covariates for the final model: sex, ethnicity, HBV status, and heavy alcohol consumption. Interaction terms were added to the final model and significance was evaluated using the log rank test. Finally, stratified analysis by sex was performed because of a statistically significant interaction with sex. All statistical analyses were conducted using SAS V.9.4 software, and two-sided p values <0.05 were regarded as statistically significant without adjustment for multiple comparisons.
was statistically significant associated with cirrhosis. In the unadjusted analysis, the OR of quintile 5 versus quintile 1 of AFB1-lys adduct was 11.55 (95% CI 4.05 to 32.89), while in the adjusted analysis the OR comparing the highest quintile of AFB1-lys adduct with the lowest quintile was 12.41 (95% CI 3.23 to 47.74). In both models, there was a significantly increasing trend in the relationship with increasing quintile (p trend=0.001). Using a three-knot restricted linear cubic regression spline, ORs were similar to those of the quintile analysis (data not shown). In addition, adding interaction terms between AFB1-lys adducts and the covariates in the final model yielded only one statistically significant interaction, which was between AFB1-lys adducts and sex (p=0.01).

The sex-specific analysis of the association between cirrhosis and AFB1-lys adducts is presented in table 4. For instance, among women, the adjusted OR comparing the highest quintile of AFB1, with the lowest quintile was 5.61 (95% CI 1.24 to 25.38), while among men the equivalent comparison had an adjusted OR of 9.64 (95% CI 1.21 to 76.94).

**DISCUSSION**

In the current study, cases had significantly higher levels of AFB1-lys adducts than did the controls. In addition, there was a statistically significantly increasing trend in the association (OR) between AFB1-lys adduct levels and cirrhosis that remained after adjustment for sex, ethnicity, HBV status and heavy alcohol consumption. In addition, evidence of effect modification by sex was observed, with the association between AFB1-lys adduct levels and cirrhosis being more pronounced among men than women.

The results of the current study are consistent with other studies from Africa and Asia, where AFB1 exposure has historically been high. In The Gambia, a study found that probable exposure to AFB1 significantly increased the risk of cirrhosis and that HBV infection had a synergistic effect on the AFB1–cirrhosis association.19 Similarly, a study in Egypt reported a significantly higher proportion of AFB1 signature mutation in TP53 among persons with chronic liver disease compared with controls.20 A Turkish study also reported a significantly higher mean level of AFB1 among individuals with cirrhosis compared with controls.15 Similarly, a study in Taiwan found that high serum AFB1 levels were associated with advanced liver disease.14 In addition, a recent nested case–control study in Taiwan reported a dose–response association between AFB1-albumin adduct levels and cirrhosis.15 Fewer studies have been reported from the Americas, and the results have not been consistent. A study in Mexico found that persons with cirrhosis had high urinary levels of AFB1 adducts.21 In Brazil, an autopsy study found an association between AFB1 residues and chronic liver diseases, including cirrhosis.22 In contrast, a US study reported that the AFB1 signature mutation in TP53 was not evident in the tissue of individuals with cirrhosis.23

In the current study, the AFB1 biomarker used reflects the formation of mutagenic AFB1-DNA adducts, and the risk of liver carcinogenesis has been demonstrated to increase with the level of aflatoxin exposure.24 A mechanism underlying the possible development of cirrhosis induced by AFB1 is not clear. In animal studies, parenchymal changes in the liver caused by steatosis, such as liver cell damage, mononuclear cell infiltration and fibrosis, have been observed after administration of AFB1.25-27 Furthermore, a recent study has suggested that myofibroblast-like cells may be involved in fibrosis due to AFB1 exposure.31 Other studies have postulated similar
mechanisms, including formation of DNA adducts, protein adducts, and lipid peroxidation. In addition, it has been suggested that AFB1 may act both as a procarcinogen to induce DNA damage and as a liver-damaging agent. Liver injury has also been shown in experimental animal studies to increase cytochrome p450 enzyme activity, which increases the activation of AFB1 and results in greater injury to the liver.

Sex difference in the prevalence of cirrhosis has been described in several studies. For example, a US population-based survey reported that cirrhosis was nearly seven times more common among men than women. The study also reported that 54% of the cases with cirrhosis were attributable to viral hepatitis, excessive alcohol consumption and diabetes, all of which have been reported to be more common in men than in women. In general, the prevalence and severity of NAFLD also appear to be higher in men compared with women. Sex differences in AFB1 levels and in the metabolism of AFB1 have also been observed in some studies. Our previous work in Guatemala found that men had significantly higher circulating levels of AFB1-lys adducts than women. Animal studies have shown that castration of male rats reduced the hepatic metabolism of AFB1 (approximately 50%), and have reported that male rats are more likely to develop AFB1-induced glutathione-S-transferase-P-positive hepatocytes (a marker of preneoplastic foci) than do female rats. This evidence may help to explain the current finding of the AFB1–cirrhosis association being more pronounced among men than women.

To our knowledge, this is the first study to assess the association between AFB1 and cirrhosis in Guatemala, a population with low prevalence of viral chronic hepatitis and a low rate of heavy alcohol consumption. The strengths of the current study include the use of a robust biomarker of AFB1 levels, open access to the data, and a comprehensive set of covariates.

### Table 3

<table>
<thead>
<tr>
<th>AFB1-albumin adducts</th>
<th>Range (pg/mg albumin)</th>
<th>Cases</th>
<th>Controls</th>
<th>Crude model</th>
<th>Adjusted model*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OR 95% CI</td>
<td>OR 95% CI</td>
</tr>
<tr>
<td>Quintile 1</td>
<td>0.49–2.68</td>
<td>5</td>
<td>54</td>
<td>1.00 –</td>
<td>1.00 –</td>
</tr>
<tr>
<td>Quintile 2</td>
<td>2.75–4.98</td>
<td>15</td>
<td>45</td>
<td>3.60 1.21 to 10.67</td>
<td>4.92 1.32 to 18.35</td>
</tr>
<tr>
<td>Quintile 3</td>
<td>5.07–9.58</td>
<td>21</td>
<td>39</td>
<td>5.82 2.02 to 16.76</td>
<td>4.85 1.31 to 17.88</td>
</tr>
<tr>
<td>Quintile 4</td>
<td>9.66–19.66</td>
<td>27</td>
<td>33</td>
<td>8.84 3.10 to 25.20</td>
<td>12.01 3.34 to 43.14</td>
</tr>
<tr>
<td>Quintile 5</td>
<td>19.68–171.58</td>
<td>31</td>
<td>29</td>
<td>11.55 4.05 to 32.89</td>
<td>12.41 3.23 to 47.74</td>
</tr>
</tbody>
</table>

P value for trend 0.001

Interaction terms were included for the covariates; only AFB1 and sex were statistically significant (p=0.01).

*Adjusted for sex, ethnicity, HBV status, and heavy alcohol consumption.

AFB1, aflatoxin B1; HBV, hepatitis B virus.

### Table 4

<table>
<thead>
<tr>
<th>AFB1-albumin adducts</th>
<th>Range (pg/mg albumin)</th>
<th>Cases</th>
<th>Controls</th>
<th>Crude model</th>
<th>Adjusted model*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OR 95% CI</td>
<td>OR 95% CI</td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quintile 1</td>
<td>0.77–2.40</td>
<td>4</td>
<td>30</td>
<td>2.70 0.74 to 9.82</td>
<td>2.31 0.52 to 10.27</td>
</tr>
<tr>
<td>Quintile 2</td>
<td>2.42–4.36</td>
<td>9</td>
<td>25</td>
<td>1.33 0.27 to 6.67</td>
<td>2.85 0.36 to 22.41</td>
</tr>
<tr>
<td>Quintile 3</td>
<td>4.47–7.77</td>
<td>11</td>
<td>24</td>
<td>4.09 1.16 to 14.39</td>
<td>3.95 0.96 to 16.35</td>
</tr>
<tr>
<td>Quintile 4</td>
<td>7.83–13.97</td>
<td>12</td>
<td>22</td>
<td>6.66 1.93 to 23.07</td>
<td>5.61 1.24 to 25.38</td>
</tr>
<tr>
<td>Quintile 5</td>
<td>14.62–137.42</td>
<td>16</td>
<td>18</td>
<td>11.73 2.77 to 49.62</td>
<td>25.44 3.26 to 198.64</td>
</tr>
</tbody>
</table>

P value for trend 0.002

Male

| Quintile 1           | 0.49–3.15             | 3     | 22       | 1.00 –      | 1.00 –          |
| Quintile 2           | 3.42–6.59             | 4     | 22       | 1.33 0.27 to 6.67 | 2.85 0.36 to 22.41 |
| Quintile 3           | 6.76–12.20            | 12    | 14       | 6.29 1.50 to 26.31 | 24.85 3.10 to 199.00 |
| Quintile 4           | 12.49–29.60           | 16    | 10       | 11.73 2.77 to 49.62 | 25.44 3.26 to 198.64 |
| Quintile 5           | 29.98–171.58          | 12    | 13       | 6.77 1.61 to 28.54 | 9.64 1.21 to 76.94 |

P value for trend <0.001

*Adjusted for ethnicity, HBV status, and heavy alcohol consumption.

AFB1, aflatoxin B1; HBV, hepatitis B virus.
exposure and the use of a community-based control group that is representative of the underlying general population. In addition, the diagnoses of cirrhosis were determined by ultrasound. Although ultrasound is not the gold standard for diagnosing cirrhosis, it has been reported that the diagnostic accuracy of ultrasound in the detection of cirrhosis is clinically acceptable, with a specificity of 72%–89%.44

Limitations of the current study include that the AFB1-lys biomarker levels were determined at a single point in time, which may not accurately reflect the cumulative AFB1 exposure over time. However, maize is the most important staple in the Guatemalan diet, it is unlikely that dietary exposure varied greatly over time. In addition, lack of information on other factors among the cases, such as body size and clinical parameters, precluded the ability to examine their effects on the AFB1–cirrhosis relationship. As there was no significant relationship between body size and AFB1, among the controls, however, it is unlikely that body size would have an effect on the AFB1–cirrhosis relationship.

In conclusion, the current study found that cirrhosis was associated with AFB1 in Guatemala, a country with a high burden of liver disease. Interventions to mitigate exposure to AFB1, as well as efforts to understand the role of other risk factors for cirrhosis may be important to reduce the burden of the disease in Guatemala.

**Author affiliations**

1 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA
2 Centro de Investigaciones Biomédicas, Facultad de Ciencias Médicas, Universidad de San Carlos de Guatemala, Guatemala, Guatemala
3 INCAP Research Center for the Prevention of Chronic Diseases, Institute of Nutrition of Central America and Panama, Guatemala, Guatemala
4 Department of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
5 Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
6 Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA

**Contributors**

Conceptualisation: EH, KE, CIV, CSA, KAM. Methodology: BIG, CSA, KAM. Formal analysis: CSA. Writing the original draft: CSA, KAM. Review and editing: ARA, MFKL, JWS, PE, ML, NF, EG, MD, JDG, MRZ.

**Funding**

The study was funded by Dirección General de Investigación (DGI), San Carlos University of Guatemala; the US National Institute of Health (grants P30CA006973-52S3 and T32ES007141); and the Intramural Research Program of the National Cancer Institute, US National Institutes of Health.

**Competing interests**

None declared.

**Patient consent for publication**

Not required.

**Ethics approval**

The cirrhosis study was approved by the institutional review boards of both public hospitals, and the cross-sectional study was approved by the institutional review boards of Johns Hopkins University Bloomberg School of Public Health and the Institute of Nutrition of Central America and Panama (INCAP).

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Data availability statement**

Data that support the findings of this study are available upon request from the authors.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

**ORCID iD**

Christian S Alvarez http://orcid.org/0000-0002-5338-0444

**REFERENCES**

24. Wild CP, Miller JD, Groopman JD. Mycotoxin control in low- and middle-income countries. Lyon (Fr: International agency for research on cancer. 2015.


